tbuckley/cabot-search huggingface dataset:
SP0058 Review of the different imaging modalities to detect calcium deposition diseases
Authors: P Omoumi
Journal: Annals of the Rheumatic Diseases (2017)

Crystal deposits in and around the joints are common and most often encountered as incidental imaging findings in asymptomatic patients. However, they can also cause chronic or acute arthropathy, generating symptoms. In the chronic setting, imaging features are usually characteristic and allow the differentiation of the type of crystal arthropathy. In the acute phase and in the early stages of the crystal deposition, the signs are often non-specific, and the final diagnosis still relies on the analysis of synovial fluid. Radiography is the main imaging modality for the workup of these conditions. It can confirm the diagnosis and often characterizes the type of crystal arthropathy. In recent years, US has played an increasingly important role in this setting, and is a useful tool in superficially located crystal-induced arthropathies. CT nicely complements radiography for deeper sites, especially the axial skeleton. DECT is a promising tool for the characterization of crystal arthropathies, in particular gout as it permits a quantitative assessment of deposits, and may help in the follow up of patients. When performed in the acute stage, MRI may show severe inflammatory changes that could be misleading and correlation to radiographs or CT should help to distinguish crystal arthropathies from infectious or tumoral conditions. <h3>Disclosure of Interest</h3> None declared
AB1105 Factors impacting patients' decision to start treatment vary by race
Authors: R Cozmuta, L Fraenkel
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Previous research has found that young minority women tend to be more risk averse compared to their Caucasian counterparts. The reasons underlying these differences, however, are not understood. <h3>Objectives</h3> The objective of this study was to examine whether factors influencing perceived treatment importance vary by race. <h3>Methods</h3> Women between the ages of 20 and 45 completed a survey. The survey recorded sociodemographic data, trust in healthcare systems and beliefs in medications. It also included a hypothetical scenario in which subjects were asked to rate the importance of taking a medication for a patient with joint pain, migraines and fatigue that benefits 70% of people and is well tolerated except for the rare risk (1 per 100,000) of a neurologic disease that may cause weakness, trouble with vision and numbness. Associations between patient characteristics, medication beliefs, and trust with perceived importance of taking the medication were evaluated for each race. Variables found to be statistically significant were subsequently evaluated using multiple linear regression. <h3>Results</h3> 299 women completed the survey. Baseline characteristics by ethnicity are described in Table 1.Hispanic women had more negative medication beliefs than did Non-Hispanic Whites, and both Non-Hispanic Black and Hispanic subjects had lower levels of hope compared to Non-Hispanic White subjects (difference between means &lt;0.05). Associations between subject characteristics and perceived importance of taking the medication are presented in Table 2. In a multilinear regression model (including education, difficulty paying for medications, medication beliefs, trust, hope and worry), hope was associated with perceived importance of taking the medication in all three ethnic groups. Additional findings differed by race, with medication beliefs in Non-Hispanic White subjects; difficulty paying for medications in Non-Hispanic Black subjects, and worry in Hispanic subjects being associated with perceived importance of taking the medication. <h3>Conclusions</h3> Our findings confirm the important influence of emotion on decision making, and suggest that while hope is universally associated with perceived importance of taking a medication, other factors differed, highlighting differences in the decision making process across ethnic groups. <h3>Disclosure of Interest</h3> None declared
High <i>BCR–ABL/GUSIS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Paolo Vigneri, Fabio Stagno, Stefania Stella, Alessandra Cupri, Stefano Forte, Michele Massimino, Agostino Antolino, Sergio Siragusa, Donato Mannina, Stefana Stella Impera, Caterina Musolino, Alessandra Malato, Giuseppe Mineo, Carmela Tomaselli, Pamela Murgano, Maurizio Musso, Fortunato Morabito, Stefano Molica, Bruno Martino, Livia Manzella, Martin C. Müller, Andreas Hochhaus, Francesco Di Raimondo
Journal: Clinical Cancer Research (2017)

Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an unmet need for baseline molecular parameters associated with inadequate imatinib responses.Experimental Design: We correlated BCR-ABL/GUSIS and BCR-ABL/ABL transcripts at diagnosis with the outcome-defined by the 2013 European LeukemiaNet recommendations-of 272 patients newly diagnosed with CML receiving imatinib 400 mg/daily. Applying receiver-operating characteristic curves, we defined BCR-ABL/GUSIS and BCR-ABL/ABL levels associated with lower probabilities of optimal response, failure-free (FFS), event-free (EFS), transformation-free (TFS), and overall survival (OS).Results: With a median follow-up of 60 months, 65.4% of patients achieved an optimal response (OR), 5.6% were classified as "warnings," 22.4% failed imatinib, and 6.6% switched to a different TKI because of drug intolerance. We recorded 19 deaths (6.9%), seven (2.5%) attributable to disease progression. We found that higher BCR-ABL/GUSIS levels at diagnosis were associated with inferior rates of OR (P < 0.001), FFS (P < 0.001), and EFS (P < 0.001). Elevated BCR-ABL/GUSIS levels were also associated with lower rates of TFS (P = 0.029) but not with OS (P = 0.132). Similarly, high BCR-ABL/ABL levels at diagnosis were associated with inferior rates of OR (P = 0.03), FFS (P = 0.001), and EFS (P = 0.005), but not with TFS (P = 0.167) or OS (P = 0.052). However, in internal validation experiments, GUS outperformed ABL in samples collected at diagnosis as the latter produced 80% misclassification rates.Conclusions: Our data suggest that high BCR-ABL transcripts at diagnosis measured using GUS as a reference gene identify patients with CML unlikely to benefit from standard-dose imatinib. Clin Cancer Res; 23(23); 7189-98. ©2017 AACR.
All TIEd up: mechanisms of Schlemm’s canal maintenance
Authors: Jeremiah Bernier-Latmani, Tatiana V. Petrova
Journal: Journal of Clinical Investigation (2017)

Glaucoma is a leading cause of blindness, with an estimated world-wide prevalence of 3.5% in members of the population older than 40 years of age. Elevated intraocular pressure as the result of abnormal resistance to aqueous humor drainage is a major contributing, and the only preventable, factor in glaucoma development. Schlemm's canal (SC), a lymphatic-like vessel encircling the anterior portion of the eye, plays a key role in promoting aqueous humor outflow and maintenance of normal intraocular pressure. The risk of developing glaucoma increases with age; therefore, understanding mechanisms of SC maintenance and how aging affects SC function are of special importance, both for prevention and novel treatment approaches to glaucoma. Using a compelling array of genetic models, Kim et al. report in this issue of the JCI that continuous angiopoietin/TIE2 signaling is required for maintaining SC identity and integrity during adulthood and show that its age-related changes can be rescued by a TIE2 agonistic antibody.
Endoscopic ultrasonography-guided photodynamic therapy for recurrent intraductal papillary mucinous neoplasm of the pancreas
Authors: Sun-Ho Lee, Hoonsub So, Seungwhan Shin, Nah Lee, Do Park
Journal: Endoscopy (2017)

Recurrence rates after partial pancreatectomy in patients with a noninvasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas are reported as being 5.4 % to 10.7 % [1] [2] [3]. A recent case demonstrated the possibility of using photodynamic therapy (PDT) as an alternative therapeutic option for IPMN [4]. Herein, we present a patient who was treated with endoscopic ultrasonography (EUS)-guided PDT, which was used as an alternative, minimally invasive option for recurrent IPMN of the pancreas.
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score
Authors: Kurt Miller, Joan Carles, Jürgen E. Gschwend, Hendrik Van Poppel, Joris Diels, Sabine D. Brookman-May
Journal: European Urology (2017)
THU0554 Immunoglobulin g4-related disease in hong kong – clinical features, treatment practices and associations
Authors: PH Li, C Ho, C-S Lau
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a systemic immune-mediated disease unifying what were previously considered to be unrelated individual organ disorders. The diagnosis and treatment of this characteristic fibroinflammatory condition continues to evolve, but generally remains an under-recognised disease. Local data outside Japanese and Caucasian populations is lacking and few studies have examined factors to predict disease severity or disease prognostication. <h3>Objectives</h3> We conducted this study to review the clinical features, treatment practices and factors associated with more extensive disease involvement in Hong Kong. <h3>Methods</h3> We retrospectively evaluated all patients with IgG4-RD over the past 13 years in our centre and combined this with patient data extracted from previous local publications. We analysed the clinical features, treatment practices and factors associated with the number of organ systems involved. <h3>Results</h3> One hundred and four patients (55 from our centre and 49 from literature review) were identified. Patients were predominantly older men (mean age 61.9 years, male:female ratio 3:1). Hepatobiliary and pancreatic (40.4%), salivary gland (33.6%), lymph nodes (29.8%) and eye (19.2%) were the most common systems involved. Lymphadenopathy was associated with glucocorticoid use (OR=2.65, p=0.034). Over 90% of patients had a serum greater than 135 mg/dl and a IgG4/total IgG ratio greater than 8%. Pre-treatment serum IgG4 levels correlated with the number of organ systems involved (β=0.347, p=0.004), and specifically with salivary gland involvement (mean 1109 mg/dl vs. 599 mg/dl, p=0.012). <h3>Conclusions</h3> We identified pre-treatment serum IgG4-RD to be associated with multi-system disease, especially with salivary gland involvement, highlighting the potential for its use in disease prognostication and monitoring. The reason for this particular correlation remains uncertain but highlights the importance of screening for salivary gland involvement in all IgG4-RD patients, especially in the presence of higher serum IgG4 levels. We also describe the clinical features and treatment modalities of the largest cohort of IgG4-RD in Hong Kong thus far. Increased physician awareness and multidisciplinary efforts are required for optimal management of this masquerading disease. Future studies, especially focusing on treatment strategies within the contexts of different epidemiology and patient characteristics, are urgently needed. <h3>Disclosure of Interest</h3> None declared
AB0350 Functional disability measured by health assessment questionnaire (HAQ) correlates with disease activity in elderly rheumatoid arthritis patients
Authors: N Alpay-Kanıtez, Ö Pehlivan, A Omma, S Can-Sandıkçı, S Yılmaz-Öner, C Bes, S Çelik
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis (RA)9s prevalence increases with age and the recognition of functional disability related to RA could be challenging in elderly patients (1). <h3>Objectives</h3> In this study, we aimed to look at the correlation between disease activity and the functional disability by using HAQ score in elderly RA patients. <h3>Methods</h3> Elderly RA patients, ≥65 years old at their routine visits were included to the study. The composite “disease activity score” in 28 joints (DAS-28) and “Physician Global Assessment” (PhGA) were used to determine disease activity. Health assessment questionnaire (HAQ) scores were calculated to describe the functional disability and compared across the disease activity groups according to DAS-28. <h3>Results</h3> Two hundred and fifty eight RA patients with the mean age of 71±5 (65–90) were included. Seropositivity rate was 71% and 47% of the patients had erosive disease. Joint deformity was seen in 72 (28%) of patients and 28 (11%) patients had undergone total arthroplasty. Lung involvement (8.5%) and Sjogren9s syndrome (7.4%) were found as the most frequent extra-articular manifestations. Hypertension (66%) and osteoporosis (36%) were the common co-morbidities. The proportion of patients with high and moderate disease activity was found as 70%. HAQ and PhGA scores were significantly correlated with the disease activity (Figure). <h3>Conclusions</h3> We provided a novel data concerning the usefulness of HAQ for prediction of disease activity in RA patients who are elderly as well. In the future, our report will be supported by the studies which suggest that HAQ score improve with effective treatment in elderly RA patients. <h3>References</h3> Uhlig T, Loge JH, Kristiansen IS, Kvien TK. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 2007;34: 1241–1247. <h3>Disclosure of Interest</h3> None declared
The path to longer and healthier lives for all Africans by 2030: the Lancet Commission on the future of health in sub-Saharan Africa
Authors: Irene Akua Agyepong, Nelson Sewankambo, Agnes Binagwaho, Awa Marie Coll-Seck, Tumani Corrah, Alex Ezeh, Abebaw Fekadu, Nduku Kilonzo, Peter Lamptey, Felix Masiye, Bongani Mayosi, Souleymane Mboup, Jean-Jacques Muyembe, Muhammad Pate, Myriam Sidibe, Bright Simons, Sheila Tlou, Adrian Gheorghe, Helena Legido-Quigley, Joanne McManus, Edmond Ng, Maureen O'Leary, Jamie Enoch, Nicholas Kassebaum, Peter Piot
Journal: The Lancet (2017)
FRI0340 B-cell activating factor as a biomarker of activity of systemic necrotizing vasculitis (SNV)
Authors: L Petelytska, O Iaremenko, K Iaremenko
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Non-specific marker of inflammation such as C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) have limited value in assessment of vasculitis activity. Normal ESR values do not exclude the diagnosis of active vasculitis, and its increase may be due to concomitant infection. <h3>Objectives</h3> To evaluate the levels of B-cell activating factor and ESR in pts with different activity of SNV. <h3>Methods</h3> The serum levels of B-cell activating factor (BAFF) and ESR were measured in 48 pts with SNV (granulomatosis with polyangiitis – 22, eosinophilic granulomatosis with polyangiitis – 9, microscopic polyangiitis – 6, polyarteritis nodosa – 11). The 48 pts included 18 male and 30 female with median age 49; 24 were positive for cytoplasmic antineutrophil cytoplasmic antibodies and 11 for perinuclear antineutrophil cytoplasmic antibodies. At screening, 9 pts were without any treatment, 26 pts were receiving glucocorticoids (GCs) and 13 pts were receiving some cytotoxic agents and GCs. Clinical activities of pts were calculated by the Birmingham Vasculitis Activity Score (BVAS). All pts were divided into 3 groups according to the value of BVAS: group 1 (BVAS≤11; n=12), group 2 (BVAS =12–23; n=23) and group 3 (BVAS≥24; n=13). The outcomes of this study were the differences in marker levels between groups estimated by analysis of the absolute changes in marker levels and the areas under receiver operating characteristic (ROC) curves. <h3>Results</h3> The levels of BAFF were significantly higher in group 3 (0.88±0.19 ng/ml) compared with group 1 (0.68±0.13 ng/ml, p&lt;0.05), but did not distinguish from the group 2 (0.90±0.35). There were not significant differences in ESR between groups. ROC analysis indicated that the AUC for ESR is 0.63±0.10 (p=0.17) and for BAFF – 0.72±0.12 (p&lt;0.05), which indicates fair capacity for BAFF differentiate groups of pts with low activity or remission of SNV and pts with severe SNV (sensitivity - 61.5%, specificity - 88.9%), while it was poor for ESR (sensitivity - 85.7%, specificity - 46.4%). <h3>Conclusions</h3> There are significant differences in levels of BAFF between pts with BVAS≥24 and pts with BVAS≤11. According to ROC analysis evaluation of serum BAFF level distinguishes pts with active SNV from pts with low activity or remission better than determination of ESR. <h3>Disclosure of Interest</h3> None declared
Evolutionary Patterns of Cytogenetically Normal Acute Myeloid Leukemia Correlate with Time to Relapse
Authors: Sebastian Vosberg, Luise Hartmann, Klaus H Metzeler, Daniela Schumacher, Friederike Pastore, Kathrin Bräundl, Evelyn Zellmeier, Bianka Ksienzyk, Nikola P Konstandin, Stephanie Schneider, Alexander Graf, Stefan Krebs, Helmut Blum, Martin Neumann, Claudia D. Baldus, Stefan K. Bohlander, Stephan Wolf, Wolfgang Hiddemann, Karsten Spiekermann, Philipp A. Greif
Journal: Blood (2016)
THU0392 Do we really need dmards addition to ankylosisng spondylitis patients treated with tumor necrosis factor alpha inhibitors?
Authors: T Reitblat, O Cohen, D Aharoni, E Hadrian, G Reifman, Y Braun-Moscovici, A Balbir-Gurman
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The management of systemic inflammatory diseases, such as Rheumatoid arthritis (RA) and Ankylosing spondylitis (AS) has been revolutionized with the introduction of tumor necrosis factor alpha inhibitors (TNF-I). Significant reduction in disease activity and achievment of remission resulted in halting of joint damage and improved quality of life. Unfortunately, approximatly 15–30% of patients fail to reach desirable improvement or lose drug effectiveness with time. It may be explained by immunogenicity and production of human anti chimeric antibodies (HACA). Presence of HACA against TNF-I have been associated with low levels of the drug and lose of therapeutic response. The prevalence of HACA in RA is estimated between 20–40%, and in AS between 25–64%. The difference in the pathogenesis of RA and AS as well as diverce approach in using disease modifying anti-rheumatic drugs (DMARDs) may influence HACA production and TNF-I levels in these conditions. <h3>Objectives</h3> To compare the incidence of HACA and Infliximab, Etanercept, Adalimumab levels in patients with RA and AS with respect to concomitant DMARDs. <h3>Methods</h3> Patients9 with RA and AS data treated with TNF-I for at least 3 months in whom tests for HACA and Infliximab, Etanercept, Adalimumab levels were available were extracted from patients9 files. Data included: demographics, concomitant treatment, and disease activity scores (BASDAI for AS and DAS-28 for RA). Serum for assessment of drugs level (ELISA) and HACA (ADAb;Promonitor, Bridging, ELISA) was obtained before the next drug administration. Univariate comparison was done using Student t test for the continuous variables and Chi square test for the categorical variables (P &lt;.05 was considered significant). <h3>Results</h3> Data on 53 patients with AS (mean age 47.9±11.9 years, 41.5. % female) and 29 patients with RA (mean age 54.8±8.1 years, 75, 9% female) were available: 22 RA patients were treated with Methotrexate and 7 with other DMARDs; no one AS patient was treated with concomitant DMARDs. High level of HACA was found in 22.6% AS patients and in 34.5% RA patients (p&gt;0.05); 86.8% patients with AS reached theurapethic level of drug compared to 69% RA patients (p=0.027). Drugs levels were similar in AS and RA patients (Table). Low disease activity (DAS28-CRP&lt;3.2) was registered in 62.1% RA patients and in 81.4% AS patients (BASDAI &lt;4). <h3>Conclusions</h3> Despite significant difference in the use of concomitant DMARDs, patients with AS and RA had similar prevalence of HACA. Moreover, higher proportion of patients in AS group reached therapeutic level of TNF-I. The data supports the hypothesis, that immune responce to TNF-I may be different in AS and RA and, therefore, the addition of DMARDs to prevent development of HACA in patients with AS may be unnecessary. <h3>Disclosure of Interest</h3> None declared
AB0536 Anticardiolipin antibodies in systemic lupus erythematosus
Authors: T Ben Salem, I Naceur, M Tougorti, M Lamloum, I Ben Ghorbel, MH Houman
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Anticardiolipin (ACL) antibodies have been independently associated with high incidence of thrombotic diseases and pregnancy associated disorders in patients with systemic lupus erythematosus (SLE). <h3>Objectives</h3> This study aims to assess influence of ACL antibodies in SLE and their association with clinical, biological and immunological features. <h3>Methods</h3> A retrospective study of 246 patients with systemic lupus erythematous (revised ACR criteria) conduced in an internal medicine department over a period time of 14 years. Two groups were compared according to the positivity of ACL antibodies (group1: positive ACL/ group2: negative ACL). <h3>Results</h3> ACL antibodies were positive in 48.8% of SLE patients (screened in 168 patients). This prevalence was similar in female and male. Poor general state at diagnosis was more frequent in the ACL positive group (55.7% vs 38.6%; p=0.02). The following data were comparable in the two groups: joint involvement (91.8% vs 90.8%; p=0.7), pericarditis (33.8% vs 37.8%; p=0.6) and pleural effusion (24.1% vs 29.5%; p=0.44). Alopecia (38.6% vs 27.9%; p=0.2), central nervous system involvement (12.5% vs 18.8%; p=) and peripheral neuropathy (6.4% vs 11.1%; p=) were more frequent in the group 2 without significant difference. Prevalence of lupus nephritis was more important in the group 1 (52.8% vs 38.8%; p=0.07). Thromboembolic complications: deep venous thrombosis (13.8% vs 11.9%; p=0.72) and pulmonary embolism (10.8% vs 7.1%; p=0.51) were more frequent in patients with ACL antibodies without significant difference. Obstetrical complications were more frequent in group 1 but differences were not statistically significant; spontaneous abortions (29.5% vs 20.4%; p=0.29), intra-uterin death (13.6% vs 9.3%; p=0.5), premature birth (6.8% vs 1.9%; p=0.3). There were no associations between hematologic disorders and ACL antibodies; leucopenia (51.3% vs 39.5%; p=0.13) and), lymphopenia (81% vs 80.2%; p=0.9), anemia (77.2% vs 74.4; p=0.6) and thrombopenia (22.8% vs 23.5%; p=0.9) were comparable in the two groups. Frequencies of anti-ds DNA antibody and of antibodies to extractable nuclear antigens were similar in the two groups. Only anti-B2GP1 antibodies were significantly associated to ACL antibodies (51.3% vs 17.2%; p&lt;0.001). <h3>Conclusions</h3> ACL antibodies were found in 30–40% of patients with SLE, this is comparable to our group. No significant associations of ACL antibodies.to thrombotic events or obstetrical complications were found in our patients <h3>Disclosure of Interest</h3> None declared